Third generation, currently in development which targets the IL-23 pathway, includes synthetic small molecules such as oral IL-23R antagonists, small molecule inhibitors of signaling molecules activated downstream of the IL-23R, the TYK2 inhibitors deucravacitinib, PF-06826647 and type I interferons which may have advantages over biologics; however, it will be important to determine if this is true in IBD patients [307]. This evidence concerns the gene IL23R and inflammatory bowel disease.